BMS Receives EMA’s CHMP Positive Opinion of Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma
- The EMA’s CHMP has recommended the approval of Breyanzi for adult patients with DLBCL, HGBCL, PMBCL & FL3B who relapsed within 12mos. from completion of, or are refractory to 1L chemoimmunotherapy
- The opinion was based on the P-III study (TRANSFORM) evaluating Breyanzi vs SoC consisting of salvage CT, followed by high-dose CT + HSCT in 184 patients. The EC’s final decision is expected within ~2mos. following receipt of the CHMP opinion
- The EC’s decision will be valid to all EU member states, Iceland, Norway, and Liechtenstein. Breyanzi is a CD19-directed CAR T cell therapy with a 4-1BB costimulatory domain & was approved in Japan for 2L treatment of r/r LBCL & in Japan, EU, Switzerland & Canada for r/r LBCL
Ref: bristol myers squibb | Image: bristol myers squibb
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.